Other SSAO inhibitor Programs

Pharmaxis is currently pursuing additional opportunities in its SSAO inhibitor program including:

AQ05646

SSAO/MPO – respiratory inflammation, cardiovascular inflammation and inflammatory bowel diseases

Pharmaxis has developed a dual SSAO and myeloperoxidase (MPO) inhibitor that has the potential to enhance the SSAO inhibition efficacy through enhanced chemistry to target the additional myloperoxidase (MPO) pathway.

A lead candidate has been identified that demonstrates efficacy in several preclinical models of inflammation. Further efficacy studies are underway together with preclinical tox studies so that the compound may proceed into phase 1 clinical trials within the next 12 months.